Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Press Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2014 Archives

Nov 20, 2014
Data presented at the EORTC-NCI-AACR International Symposium Demonstrate High Sensitivity and Strong Quantitative Performance with Trovagene's Precision Cancer Monitoring Platform
Nov 12, 2014
Stifel 2014 Healthcare Conference and Cannacord Genuity Medical Technologies and Diagnostics Forum
Oct 27, 2014
Prospective blinded study demonstrates ability to accurately determine mutational status and monitor response to BRAF inhibitor therapy from urinary cell-free DNA
Oct 6, 2014
BIO Investor Forum to be held October 7-8 in San Francisco, California
Oct 1, 2014
BRAF V600E assay improves determination of mutational status and allows monitoring of treatment response
Sep 29, 2014
Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients
Jul 1, 2014
Strengthens balance sheet to fund clinical programs, commercialization efforts, and continued expansion of oncogene mutation portfolio for cancer monitoring
Jun 16, 2014
Company continues to engage leading cancer treatment centers to investigate non-invasive methods of cancer mutation detection in order to advance patient care
Jun 2, 2014
Clinical Study Results Published in 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology
May 28, 2014
Non-invasive detection and monitoring of actionable oncogene mutation in Erdheim-Chester disease serves as a model case for clinical utility
May 20, 2014
Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene mutation status for therapy selection